Design, Synthesis, and Biological Evaluation of Indolin‐2‐One–Matrine Derivatives as Potential VEGFR‐2‐Targeting Agents for Hepatocellular Carcinoma
ChemMedChem · 28.04.2026 · 21 (8)
DOI: 10.1002/cmdc.70283 ↗Kurz gefasst
Fachartikel in der Zeitschrift ChemMedChem, online erschienen am 25.04.2026. Verfasst von Ziyi Wang und 4 weiteren Autor:innen. Beteiligte Einrichtung: College of Chemistry and Chemical Engineering, Guangxi University, Nanning, China. Hauptthemen laut MEDLINE: Vascular Endothelial Growth Factor Receptor-2, Liver Neoplasms, Antineoplastic Agents, Drug Design. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: Guangxi Key Laboratory of Pharmaceutical Precision Detection and Screening, Shenzhen Key Laboratory of Southern Subtropical Plant Diversity, Key Laboratory of Pollution Exposure and Health Intervention of Zhejiang Province.
Abstract (Originalsprache)
Inhibition of the VEGF/VEGFR‐2 pathway is a validated strategy to suppress tumor angiogenesis and progression; however, long‐term use of several VEGFR‐2 tyrosine kinase inhibitors is limited by resistance and systemic toxicity. Here, a series of novel indolinone–matrine hybrids were designed and synthesized via a molecular hybridization strategy. The antiproliferative activities were evaluated against human hepatocellular carcinoma (HCC) cell lines (HepG‐2, HuH7, and MHCC97H). Among them, J9 showed the most potent activity with IC 50 values of 5.81, 2.14, and 3.03 μM, respectively, and relatively low cytotoxicity toward HEK‐293 cells (IC 50 = 27.90 μM) and HL7702 cells (IC50 = 52.23 μM). In HuH7 cells, J9 significantly inhibited colony formation and migration, induced G1‐phase arrest, and promoted apoptosis in a dose‐dependent manner. Western blot analysis indicated that J9 treatment was associated with downregulation of VEGFR‐2 and activation of caspase‐dependent apoptosis (increased cleaved caspase‐3 and cleaved PARP). Moreover, J9 inhibited VEGFR‐2 kinase in vitro (IC 50 = 253.51 ± 1.21 nM), and docking/MD simulations suggested stable binding within the VEGFR‐2 ATP‐binding pocket. Collectively, J9 represents a promising matrine‐derived antitumor candidate with potential VEGFR‐2‐targeting activity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Chemistry and Chemical Engineering, Guangxi University, Nanning, China.
- Medical College, Guangxi University, Nanning, China.
- School of Basic Medical Sciences, Youjiang Medical University for Nationalities, Baise, China.
- Guangxi Key Laboratory of Pharmaceutical Precision Detection and Screening, Guangxi Medical University, Nanning, China.
ORCID-Profile: Yongquan Wei, Lihe Jiang, Lisheng Wang
Förderung
- Guangxi Key Laboratory of Pharmaceutical Precision Detection and Screening
- Shenzhen Key Laboratory of Southern Subtropical Plant Diversity
- Key Laboratory of Pollution Exposure and Health Intervention of Zhejiang Province
- Scientific and Technological Development under the Guidance of Central Government
Zitieren
APA
Wang, Z., Wei, Y., Xing, Z., Jiang, L., & Wang, L. (2026). Design, Synthesis, and Biological Evaluation of Indolin‐2‐One–Matrine Derivatives as Potential VEGFR‐2‐Targeting Agents for Hepatocellular Carcinoma. ChemMedChem, 21(8). https://doi.org/10.1002/cmdc.70283
Vancouver
Wang Z, Wei Y, Xing Z, Jiang L, Wang L. Design, Synthesis, and Biological Evaluation of Indolin‐2‐One–Matrine Derivatives as Potential VEGFR‐2‐Targeting Agents for Hepatocellular Carcinoma. ChemMedChem. 2026;21(8). doi:10.1002/cmdc.70283
BibTeX
@article{Wang2026,
author = {Wang, Ziyi and Wei, Yongquan and Xing, Zexu and Jiang, Lihe and Wang, Lisheng},
title = {Design, Synthesis, and Biological Evaluation of Indolin‐2‐One–Matrine Derivatives as Potential VEGFR‐2‐Targeting Agents for Hepatocellular Carcinoma},
journal = {ChemMedChem},
year = {2026},
volume = {21},
number = {8},
doi = {10.1002/cmdc.70283}
}
EUVIMED